Teva Pharmaceutical Industries Ltd (TEVA)

neg -0.42
Today's Range: 56.96 - 58.86 | TEVA Avg Daily Volume: 5,175,400
Last Update: 10/06/15 - 4:03 PM EDT
Volume: 4,475,976
YTD Performance: 1.53%
Open: $58.79
Previous Close: $58.39
52 Week Range: $47.36 - $72.31
Oustanding Shares: 839,348,282
Market Cap: 50,411,257,817
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 9
Moderate Buy 2 2 2 0
Hold 5 6 5 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.82 1.88 1.82 2.11
Latest Dividend: 0.29
Latest Dividend Yield: 1.90%
Dividend Ex-Date: 08/18/15
Price Earnings Ratio: 40.31
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
40.31 20.30 24.59
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.15% 6.30% 45.54%
Revenue -0.20 0.11 0.03
Net Income 142.80 0.10 0.03
EPS 138.50 0.15 0.05
Earnings for TEVA:
Revenue 20.27B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $1.28 $1.25 $5.31 $5.48
Number of Analysts 17 17 20 20
High Estimate $1.33 $1.38 $5.45 $6.26
Low Estimate $1.24 $1.16 $5.15 $5.04
Prior Year $1.32 $1.31 $5.07 $5.31
Growth Rate (Year over Year) -2.94% -4.71% 4.74% 3.28%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
Management team and acquisitions help make pharma company a buy.
Sometimes it pays to follow the leader. I am going to piggy back the call buyers and buy at-the-money calls in Teva Pharmaceutical.
There is building consensus around a September rate hike.

Jensen's Morning Musings Real Money Pro($)

I'm happy as always to be standing in for Doug Kass on the Daily Diary.
Jul 28, 2015 | 7:22 AM EDT
TEVA was upgraded to Outperform, BMO Capital said. $80 price target. Allergan deal makes the company a generic leader. 

Tread Carefully in the Market Real Money Pro($)

This week could easily bring additional selling.
And we are raising our price target on AGN.

Columnist Conversations

Yum's getting ridiculous again because you have to wait for the call tomorrow and no one knows what will be sa...
My view is that the bulls have it wrong and that the preoccupation with the price momentum over the last two d...
Does the YUM miss call into question the optimism regarding the Chinese consumer?


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.